Oral P2X7 Receptor Antagonists
Diabetic Retinopathy / Age-related Macular Degeneration
PreclinicalActive
Key Facts
Indication
Diabetic Retinopathy / Age-related Macular Degeneration
Phase
Preclinical
Status
Active
Company
About Breye Therapeutics
Breye Therapeutics is a Danish biotech advancing oral therapies for retinal diseases like diabetic retinopathy and age-related macular degeneration. Its lead asset, danegaptide, has reported positive Phase 1b data, and the company is also developing a platform of oral P2X7 receptor antagonists. With a seasoned leadership team and a focus on significant unmet needs in ophthalmology, Breye is positioning itself to address a large market with convenient oral alternatives to current invasive treatments.
View full company profile